Cue Biopharma (Cue Biopharma) Insider Ownership : 4.50 % (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cue Biopharma's insider ownership is 4.50%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cue Biopharma's Institutional Ownership is 16.12%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cue Biopharma's Float Percentage Of Total Shares Outstanding is 97.01%.

Cue Biopharma Insider Ownership Historical Data

The historical data trend for Cue Biopharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Insider Ownership Chart

Cue Biopharma Historical Data

The historical data trend for Cue Biopharma can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	4.79	4.87	4.87	4.85	4.85	4.85	4.85	4.85	4.50	4.50

Cue Biopharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Cue Biopharma (Cue Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

1UC:Germany 1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director